Cala Medical limited, formed in February this year, is a spin out from the University of Limerick and based at the Nexus Innovation Centre. The company have designed and patented a unique device containing a specific immobilized enzyme which treats the excessive inflammatory response in the blood of sepsis patients.
The treatment could dramatically cut the death rate from sepsis which is a highly prevalent and often fatal illness requiring intensive medical care.The number of sepsis cases globally is estimated to be over 26 million and there is an enormous medical need for new therapies to combat the high mortality rates.
Cala Medical was founded by Dr Jakki Cooney (Dept of Biological Sciences), Dr Todd Kagawa and Dr Brian Noonan, who have licensed the IP from the university and spent the past three years working on the project after securing an Enterprise Ireland Commercialisation Fund. The company has closed a seed funding round in 2017 with support from angel investors and Enterprise Ireland’s high potential start-up programme.
Dr. Brian Noonan, co-founder and Chief Executive said, “There are no equivalent therapies to ours on the market today. Cassettes that filter blood are available but they are not widely used due to limited success in treating sepsis. There are other companies pursuing therapies using extracorporeal cassettes, but these are based on cleaning or removing substances, such as bacterial material, from the blood. Our system is the only one adding something that specifically targets the human immune system and reduces the over-response no matter what the cause.”